Drug
Daratumumab and Hyaluronidase-fihj clinical trials
- studies test it
- 13
- open now
- 8
- in phase 3
- 3
- first study started
- 2017
Keep track of what changes. Save the Daratumumab and Hyaluronidase-fihj studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2023 (3)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 2
- Phase 2
- 6
- Phase 3
- 3
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 1 · Other 12
SWOG Cancer Research Network (2) · Janssen Research & Development, LLC (1) · NYU Langone Health (1) · Thomas Jefferson University (1) · Barry A. Boilson (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · Eden Biltibo (1) · Roswell Park Cancer Institute (1)
Often tested with
Tested in the same studies.
Dexamethasone (3) · Bortezomib (2) · Lenalidomide (1) · INCB057643 (1) · Carfilzomib (1) · Teclistamab (1) · Iberdomide (1) · Cyclophosphamide (1)
Studies
Open first, then newest update. How each study uses Daratumumab and Hyaluronidase-fihj is read from its arms, and is right about nine times in ten.
Testing it · 13
- Daratumumab in HLA Desensitization Prior to TransplantationEnrolling by invitationPhase 2Barry A. BoilsonNCT05300451Written as Daratumumab and hyaluronidase-fihj
- Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific AntibodiesRecruitingEarly Phase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT06398457Written as Darzalex Faspro (Daratumumab and hyaluronidase-fihj)
- Identifying Effective and Cost-Conscious Maintenance Daratumumab DosingRecruitingPhase 2Eden BiltiboNCT07485647Written as Daratumumab and Recombinant Human Hyaluronidase
- SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaRecruitingPhase 1Roswell Park Cancer InstituteNCT06622005Written as Daratumumab and Recombinant Human Hyaluronidase
- Teclistamab-Daratumumab in AL AmyloidosisRecruitingPhase 2Rajshekhar Chakraborty, MDNCT07110844Written as Daratumumab and Hyaluronidase-fihj
- Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple MyelomaRecruitingPhase 2Barbara Ann Karmanos Cancer InstituteNCT06107738Written as Daratumumab/rHuPH20 Co-formulation
- Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable TreatmentRecruitingPhase 3SWOG Cancer Research NetworkNCT05561387Written as Daratumumab and Hyaluronidase-fihj
- Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL AmyloidosisRecruitingPhase 3SWOG Cancer Research NetworkNCT06022939Written as Daratumumab and Hyaluronidase-fihj
- A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple MyelomaCompletedPhase 3Janssen Research & Development, LLCNCT03301220Written as Daratumumab SC: daratumumab + rHuPH20
- Daratumumab in STK11 Mutated NSCLCCompletedPhase 2NYU Langone HealthNCT05807048Written as Daratumumab and Hyaluronidase-fihj
- Home Based Daratumumab Administration for Patients With Multiple MyelomaCompletedPhase 4Thomas Jefferson UniversityNCT05511428Written as Daratumumab and Hyaluronidase-fihj
- Daratumumab for Polyneuropathy Associated With MGUSWithdrawnPhase 2Georgetown UniversityNCT06046287Written as Daratumumab and hyaluronidase-fihj
- Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple MyelomaTerminatedPhase 1Abdullah KhanNCT04956302Written as Daratumumab and Hyaluronidase-fihj
Given in every arm · 11 — Daratumumab and Hyaluronidase-fihj is usual care beside what is tested
- Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First RelapseRecruitingPhase 2National Cancer Institute (NCI)NCT06948084Written as Daratumumab and Recombinant Human Hyaluronidase
- Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple MyelomaNot yet recruitingPhase 2/3Alliance for Clinical Trials in OncologyNCT07887984Written as Daratumumab and Recombinant Human Hyaluronidase
- Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM TrialRecruitingPhase 2National Cancer Institute (NCI)NCT07605416Written as Daratumumab and Recombinant Human Hyaluronidase
- Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney FailureRecruitingPhase 2Eastern Cooperative Oncology GroupNCT07085728Written as Daratumumab-hyaluronidase
- Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE TrialRecruitingPhase 3ECOG-ACRIN Cancer Research GroupNCT04566328Written as Daratumumab and Hyaluronidase-fihj
- ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple MyelomaNot yet recruitingPhase 2Massachusetts General HospitalNCT07247097Written as Daratumumab and Hyaluronidase-fihj
- Daratumumab for Patients With Light Chain AmyloidosisRecruitingNot applicableNanjing University School of MedicineNCT06376214Written as Dratumumab / Hyaluronidase Injection [Darzalex Faspro]
- Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple MyelomaActive, not recruitingPhase 2National Cancer Institute (NCI)NCT06169215Written as Daratumumab and Recombinant Human Hyaluronidase
- Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple MyelomaWithdrawnPhase 1Roswell Park Cancer InstituteNCT07082270Written as Daratumumab and Recombinant Human Hyaluronidase
- Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple MyelomaTerminatedPhase 2University of California, San DiegoNCT03590652Written as Daratumumab-Hyaluronidase-Fihj@1,800 Mg-30,000 Unit/15 mL@SUBCUT@VIAL (ML)
- A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)TerminatedPhase 1/2TakedaNCT04776018Written as Daratumumab and Hyaluronidase-fihj
As the comparator · 4 — what is tested is compared with Daratumumab and Hyaluronidase-fihj
- Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple MyelomaRecruitingPhase 3PrECOG, LLC.NCT07285239Written as Arm B: Daratumumab Hyaluronidase
- A Study Comparing Pharmacokinetic and Safety of QL2109 and DARZALEX FASPRO® in Healthy AdultsRecruitingPhase 1Qilu Pharmaceutical Co., Ltd.NCT06371534Written as DARZALEX FASPRO®
- To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple MyelomaNot yet recruitingPhase 3Qilu Pharmaceutical Co., Ltd.NCT06742138Written as DARZALEX FASPRO®
- A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple MyelomaActive, not recruitingPhase 3CelltrionNCT06952478Written as Darzalex Faspro(Daratumumab)